Source: IBRO Neuroscience Reports. Conference titles: World Congress of Neuroscience IBRO. Unidades: FORP, FMRP
Subjects: CANABINOIDES, DOENÇA DE PARKINSON, ANTI-INFLAMATÓRIOS, ANTIOXIDANTES
ABNT
MATTOS, Bianca Andretto de et al. Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats. IBRO Neuroscience Reports. Amsterdam: Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.ibneur.2023.08.675. Acesso em: 15 jun. 2025. , 2024APA
Mattos, B. A. de, Nascimento, G. C. do, Crippa, J. A. de S., Hallak, J. E. C., Michel, P., Raisman-Vozari, R., et al. (2024). Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats. IBRO Neuroscience Reports. Amsterdam: Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.ibneur.2023.08.675NLM
Mattos BA de, Nascimento GC do, Crippa JA de S, Hallak JEC, Michel P, Raisman-Vozari R, Guimarães FS, Del Bel EA. Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats [Internet]. IBRO Neuroscience Reports. 2024 ; 15 S359.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.ibneur.2023.08.675Vancouver
Mattos BA de, Nascimento GC do, Crippa JA de S, Hallak JEC, Michel P, Raisman-Vozari R, Guimarães FS, Del Bel EA. Cannabidiol and cannabigerol limit l-dopa-induced dyskinesia when given separately or in combination to hemiparkinsonian rats [Internet]. IBRO Neuroscience Reports. 2024 ; 15 S359.[citado 2025 jun. 15 ] Available from: https://doi.org/10.1016/j.ibneur.2023.08.675